NEW YORK (GenomeWeb News) – Advanced Cell Diagnostics today said that the National Cancer Institute has awarded it a three-year, $3 million grant to further develop its CTCscope system for the detection and molecular characterization of circulating tumor cells.
The Small Business Innovation Research Phase II Bridge Award will be used to develop the platform into an automated system and to conduct clinical studies to demonstrate its clinical use, ACD said in a statement. Collaborators on the project include Paul Goodwin of Applied Precision, Hope Rugo and John Park of the University of California, San Francisco, David Krag of the University of Vermont, and Charles Coombes of Imperial College London.
The CTCscope system is based on ACD's RNAscope technology for in situ RNA detection. The system identifies the molecular phenotypes of circulating tumor cells to guide treatment decisions and allows for the real-time monitoring of therapy response.
Based in Hayward, Calif., ACD is a molecular pathology and tissue-based diagnostic test development firm. It previously received Phase I and Phase II grants from NCI to develop its RNAscope technology, which has been incorporated into research-use only products for in situ detection of RNA biomarkers in formalin-fixed paraffin embedded tissue.